<ѻý>Clinical Challenges: Implementing More Guideline-Endorsed SGLT2i Useѻý> New strategies needed to ensure all are on board with fourth pillar of HF treatment Apr 11, 2022
<ѻý>Two PCI Guidance Strategies on Par for Intermediate Coronary Stenosisѻý> FLAVOUR trial weighs in on FFR versus IVUS Apr 05, 2022
<ѻý>Which Drug-Coated Balloon Proved Superior in Peripheral Artery Disease?ѻý> Second-generation device goes head-to-head with popular first-gen device Apr 05, 2022
<ѻý>Study Provides 'Elusive' Link Between Kids' Health and Adult Heart Eventsѻý> CV risk factors in childhood tied to midlife CV events and CVD Apr 05, 2022
<ѻý>Transcatheter Tricuspid Repair Shows Early Promiseѻý> PASCAL device safe and linked to symptom improvement in severe tricuspid regurgitation Apr 04, 2022
<ѻý>Higher-Dose ANGPTL3 Inhibitor Cuts Lipids but With Questionable Safetyѻý> Significant safety signals in dose-ranging trial may end drug's future in CV prevention Apr 03, 2022
<ѻý>Tranexamic Acid Cuts Surgical Bleeding in Yet Another Settingѻý> But POISE-3 trial leaves open the question of cardiovascular safety Apr 02, 2022
<ѻý>From 'Pre-HF' to 'HFimpEF': Guidelines Redefine Heart Failure Stages, Classesѻý> Update also adds SGLT2 inhibitor as a pillar of therapy Apr 01, 2022
<ѻý>Cardiomyopathy: Epidemiology, Etiology, and Pathophysiologyѻý> A brief guide through the wide range of cardiomyopathies Apr 01, 2022
<ѻý>For Your Patients: How to Prepare for Your Cardiomyopathy Appointmentѻý> Questions to ask your cardiologist, and answers you might need Apr 01, 2022